A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
Public ClinicalTrials.gov record NCT03595059. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or docetaxel (Part 1b). In Part 2 (dose expansion), participants will receive ABBV-155 monotherapy or in combination therapy. The ABBV-155 monotherapy cohort will enroll participants with relapsed or refractory (R/R) small cell lung cancer (SCLC) (Part 2a); the ABBV-155 plus a taxane (paclitaxel or docetaxel) combination cohort will enroll participants with R/R non-small cell lung cancer (NSCLC) and breast cancer (Part 2b).
Study identification
- NCT ID
- NCT03595059
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 168 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 13, 2018 (Actual)
- Primary completion
- Sep 12, 2025 (Actual)
- Completion
- Sep 12, 2025 (Actual)
- Last update posted
- Dec 10, 2025
2018 – 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - Main /ID# 214024 | Birmingham | Alabama | 35233 | — |
| Highlands Oncology Group, PA /ID# 201568 | Springdale | Arkansas | 72762 | — |
| UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 206105 | Orange | California | 92868-3201 | — |
| Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 204267 | West Hollywood | California | 90048 | — |
| Univ of Colorado Cancer Center /ID# 208365 | Aurora | Colorado | 80045 | — |
| Yale University, Yale Cancer Center /ID# 201542 | New Haven | Connecticut | 06510-3206 | — |
| AdventHealth Orlando /ID# 227242 | Orlando | Florida | 32803 | — |
| Northwestern University Feinberg School of Medicine /ID# 201563 | Chicago | Illinois | 60611-2927 | — |
| Duplicate_Johns Hopkins Bayview Med Cnt /ID# 215095 | Baltimore | Maryland | 21224 | — |
| Johns Hopkins Hospital /ID# 201320 | Baltimore | Maryland | 21287 | — |
| Dana-Farber Cancer Institute /ID# 201564 | Boston | Massachusetts | 02215 | — |
| Duplicate_Henry Ford Hospital /ID# 226852 | Detroit | Michigan | 48202 | — |
| Northwell Health - Marcus Ave /ID# 204376 | New Hyde Park | New York | 11042-2060 | — |
| Carolina BioOncology Institute /ID# 201577 | Huntersville | North Carolina | 28078 | — |
| Univ Hosp Cleveland /ID# 201567 | Cleveland | Ohio | 44106 | — |
| University of Oklahoma, Stephenson Cancer Center /ID# 206820 | Oklahoma City | Oklahoma | 73104-5418 | — |
| Lifespan Cancer Institute at Rhode Island Hospital /ID# 204256 | Providence | Rhode Island | 02903-4923 | — |
| Vanderbilt Ingram Cancer Center /ID# 201575 | Nashville | Tennessee | 37232-0021 | — |
| Mary Crowley Cancer Research /ID# 214168 | Dallas | Texas | 75230 | — |
| MD Anderson Cancer Center /ID# 201558 | Houston | Texas | 77030 | — |
| NEXT Oncology /ID# 204893 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03595059, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2025 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03595059 live on ClinicalTrials.gov.